Michael T.  Constantino net worth and biography

Michael Constantino Biography and Net Worth

Director of 9 Meters Biopharma
Mr. Constantino joined our Board in June of 2020 and is a retired Ernst & Young LLP assurance partner with more than 30 years of experience. Mr. Constantino has worked closely with companies across various development stages, from early start-up to mature Fortune 250 corporations, and assisted management teams and boards of directors with SEC compliance matters, global operations and strategic planning. During his career, he worked with life science companies, CROs, technology, manufacturing and transportation firms. Mike assisted clients with over 20 IPOs, debt offerings, M & A transactions, and private equity offerings, working closely with companies across the continuum from start-up to mature public entities while assisting management teams and boards with SEC compliance matters, Sarbanes-Oxley internal controls, global operations and strategic planning. He is the Chair of the Board for the NC State Foundation, a member of the NC State Investment Fund Board and Chair of the Board of The Green Chair Project. He has served as the Treasurer for the North Carolina Biotechnology Center, Chairman of the NC State Poole College of Management Board of Advisors, the Board of Directors and Treasurer for Rise Against Hunger (formerly, Stop Hunger Now), Board of Directors and Treasurer for the Council for Entrepreneurial Development, and Chairman and Treasurer for Southeastern Bio. Mike holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina CPA.

What is Michael T. Constantino's net worth?

The estimated net worth of Michael T. Constantino is at least $0.00 as of May 23rd, 2022. Mr. Constantino owns 4,500 shares of 9 Meters Biopharma stock worth more than $0 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Constantino may own. Learn More about Michael T. Constantino's net worth.

How do I contact Michael T. Constantino?

The corporate mailing address for Mr. Constantino and other 9 Meters Biopharma executives is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. 9 Meters Biopharma can also be reached via phone at (919) 275-1933 and via email at [email protected]. Learn More on Michael T. Constantino's contact information.

Has Michael T. Constantino been buying or selling shares of 9 Meters Biopharma?

Michael T. Constantino has not been actively trading shares of 9 Meters Biopharma over the course of the past ninety days. Most recently, on Tuesday, August 24th, Michael T. Constantino bought 18,000 shares of 9 Meters Biopharma stock. The stock was acquired at an average cost of $1.14 per share, with a total value of $20,520.00. Learn More on Michael T. Constantino's trading history.

Who are 9 Meters Biopharma's active insiders?

9 Meters Biopharma's insider roster includes Michael Constantino (Director), Mark Sirgo (Director), Edward Sitar (CFO), and John Temperato (CEO). Learn More on 9 Meters Biopharma's active insiders.

Michael T. Constantino Insider Trading History at 9 Meters Biopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2021Buy18,000$1.14$20,520.00View SEC Filing Icon  
See Full Table

Michael T. Constantino Buying and Selling Activity at 9 Meters Biopharma

This chart shows Michael T Constantino's buying and selling at 9 Meters Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

9 Meters Biopharma Company Overview

9 Meters Biopharma logo
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

46 shs

Average Volume

315,915 shs

Market Capitalization

$1.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36